Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan
Status:
Completed
Trial end date:
2018-12-30
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-center, randomized, open-label, parallel-arm controlled study,
for which a total of 216 patients with type 2 diabetic nephropathy (Stage II-IV) will be
enrolled. The subjects will be randomized to three groups in 1:1:1 ratio. One group receive
Alfacalcidol 0.25ug/day and Irbesartan 150mg/day for 16 consecutive weeks. The second group
receive Alfacalcidol 0.25ug/day alone for 16 consecutive weeks. The third group receive
Irbesartan 150mg/day alone for 16 consecutive weeks. All subjects will be followed up for 4
weeks after medication is over. A total of 4 visits have been scheduled for this study at
week 0, week 8, week 16, week 20.
Phase:
Phase 4
Details
Lead Sponsor:
The Third Xiangya Hospital of Central South University